EcoR1 Capital, LLC

This profile gathers the share dealings of EcoR1 Capital, LLC across 14 companies, led by Zymeworks Inc., Anaptysbio, Inc and Prothena CORP Public Ltd Co. The record holds 41 filings, for trades running from 30 June 2020 to 20 April 2026.

The open-market side counts 29 purchases for €146.1M alongside 7 sales for €105.8M. Taken together, the purchases exceed the sales by €40.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants. In 2026 alone, the filings show no purchases and 1 sale.

Half of the purchases are above €1.3M and half below. 1 out of 29 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 26 purchases old enough to measure, the stock rose over the following 90 days in 46% of cases; the median change was -0.3%. This is a record of the past, not a forecast.

Most recently, on 22 April 2026, the filings show an open-market sale worth €55.2M in First Tracks Biotherapeutics, Inc. The last purchase on record was published on 19 May 2025, which is 523 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.